Tesamorelin
TH9507
Tesamorelin is the one GHRH analog that made it all the way to FDA approval — a growth-hormone-releasing peptide specifically shown to burn <b>visceral</b> (deep belly) fat. Marketed as Egrifta, it's the gold-standard example of a GH-axis peptide with real Phase III human data. This guide covers how tesamorelin works, what the trials showed, its approved use, dosing, safety and status.
Tesamorelin quick facts
| Reported research dosing | 0.5mg-2mg |
| Route | Subq |
| Cycle length | 3-6 Months |
| Frequency | 1x Daily AM/PM · 5 On 2 Off or Daily |
| Half-life | ~26–38 min |
| Forms | Injectable |
| Evidence level | FDA-approved (visceral/HIV-lipo); human trials |
The most clinically-backed GHRH for visceral fat. Real data, not just bro-lore.
How tesamorelin works
Tesamorelin is a stabilized GHRH (1-44) analog — the full GHRH molecule with an N-terminal modification that resists enzymatic breakdown. It binds pituitary GHRH receptors and drives a pulse of your own growth hormone. The reason it targets belly fat specifically: visceral fat has a higher density of GH receptors and a higher lipolytic rate than subcutaneous fat, so a GH pulse lands disproportionately on the deep abdominal depot.
What the research shows
This is tesamorelin's standout: real Phase III human data. In a pooled analysis of 806 participants across two trials, tesamorelin reduced visceral adipose tissue by about 15.4% versus placebo at 26 weeks — while largely sparing subcutaneous fat. That selectivity for deep abdominal fat is what makes it clinically distinctive and why it's studied off-label for visceral-fat and metabolic goals beyond its approved indication.
Approved use & brand names
Tesamorelin (brand Egrifta, and newer Egrifta SV / Egrifta WR) is FDA-approved to reduce excess abdominal fat in adults with HIV and lipodystrophy — the only GHRH-analog drug ever approved (2010). Whether it's appropriate for a person is a decision for a licensed prescriber.
Dosing (as approved / studied)
Approved dosing has been a daily subcutaneous injection: original Egrifta at 2 mg/day, Egrifta SV at 1.4 mg/day. In 2025 the FDA approved a new F8 formulation (Egrifta WR) at 1.28 mg with the convenience of weekly reconstitution instead of daily, improving adherence. Actual dosing must be set and supervised by a prescriber; these figures summarize the approved schedules for education only.
Safety & side effects
Common effects include injection-site reactions, joint pain, and fluid retention. As a GH-axis therapy it raises GH and IGF-1, so IGF-1 is monitored and it carries the class caution around IGF-1 and cancer risk; it's contraindicated in active malignancy. This is a prescription medication for good reason — medically supervised, with monitoring.
Tesamorelin vs the other GH options
Tesamorelin is the strongest, best-evidenced GHRH — FDA-approved and specifically visceral-fat selective. Sermorelin is the gentler GHRH; the CJC-1295 + Ipamorelin stack adds a GHRP for a bigger pulse; MK-677 is the oral secretagogue. Tesamorelin stands out for actually having human outcome data behind it.
Legal & regulatory status
Tesamorelin is a prescription medication, FDA-approved as Egrifta for HIV-associated lipodystrophy. Anything sold as tesamorelin outside a legitimate prescription is unapproved, and GH secretagogues are banned in competitive sport under WADA. This page is educational, not a recommendation to obtain or use it.
✅ Clinically validated
- The strongest human evidence of any growth-hormone secretagogue here. FDA-approved as Egrifta for HIV-associated lipodystrophy on the back of two phase-3 trials, where it cut visceral adipose tissue by roughly 15–18% over 26 weeks against placebo.
- A separate NIH trial in non-HIV adults with NAFLD showed reduced liver fat, which matters because it is the one result that generalises beyond the licensed population most readers do not belong to.
📊 Correlative data
- Off-label use for visceral fat in metabolically healthy adults is common and unstudied. The approval population had a specific disease driving a specific fat distribution, and how much of the effect survives in someone without it is genuinely unknown — the mechanism should carry over, the effect size probably does not.
🧪 Theoretical / extrapolated
- A GHRH analogue: it acts one step upstream of growth hormone, on the pituitary, so release stays pulsatile and under normal feedback control. That is the mechanistic argument for it over exogenous HGH, and it predicts the two things reliably observed — visceral fat responds first, and IGF-1 rises modestly rather than dramatically.
- The same feedback loop predicts the downside: it cannot exceed what your pituitary can produce, so it does far less in someone whose GH axis is already failing than in someone whose axis works.
These tiers tell you how much human evidence exists — not how well something works. This is the research space, and most of what’s in here is new rather than disproven. Something sitting at “theoretical” usually means nobody has funded the trial, not that the trial was run and failed.
The trap runs the other way too: something can be clinically validated and still do very little for you specifically. A statistically significant result in a study population is not a promise about your body.
- ✅ Clinically validated — human randomised trials or meta-analyses support it. The strongest footing available.
- 📊 Correlative — observational or epidemiological data. Suggestive, and genuinely useful for direction, but it cannot establish cause.
- 🧪 Theoretical / mechanistic — the mechanism is understood and often demonstrated in cells or animals, and the human trial doesn’t exist yet. Unproven is not the same as ineffective. Plenty of what’s standard practice today sat here five years ago.
✗ is a safety flag, not a grade. Where you see it, the concern is harm — not a disappointing trial. A compound tested for one purpose and found not to help there can still be worth studying somewhere else, so a negative result never gets rendered as a cross. It sits alongside the tier, because something can be both well-studied and genuinely risky.
My job is to tell you which one you’re looking at, and let you make the call. Grading something low isn’t me dismissing it — it’s me refusing to oversell it. This is the research space, and being able to reason forward from a mechanism matters as much as waiting for the trial.
Tesamorelin — safety, predicted from mechanism
Much of this compound class has never been through a human safety trial. Rather than say nothing — or print a generic warning — this is what its known mechanism predicts could go wrong, and what you can do about it. Predictions are labelled as predictions.
What the mechanism predicts
Derived from what this molecule does, not from a trial.
- Everything here follows from one fact: these raise GH and therefore IGF-1. The predicted problems are the known consequences of elevated GH/IGF-1, drawn from acromegaly and clinical GH therapy where it HAS been studied — insulin resistance and rising fasting glucose, fluid retention (puffy hands and face, and the ring that stops fitting), carpal tunnel symptoms from that same fluid pressing on the median nerve, and joint aches.
- The proliferation question is the serious one. IGF-1 is a growth signal, and growth signals do not distinguish between tissue you want to grow and tissue you do not. There is no evidence these compounds cause cancer. There is also a clear mechanistic reason not to run them with an active or recent malignancy, and that reasoning does not require a trial to be sound.
What has actually been reported
- Injection-site reactions, transient flushing, tingling and head-rush on dosing — most commonly with the GHRPs, which also release cortisol and prolactin at higher doses.
- Increased hunger is near-universal with the ghrelin-mimetic ones (GHRP-6, MK-677, Hexarelin). That is the mechanism working, not a side effect — the same receptor drives GH release and appetite.
How to reduce the risk
Each of these follows from the same mechanism as the prediction.
- Draw an IGF-1 baseline BEFORE you start. Once you are on, that number is the drug and you have permanently lost the comparison. This is the single highest-value thing on this list and it costs one blood draw.
- Watch fasting glucose and HbA1c, not the scale. Insulin resistance is the most likely thing to move and the one you cannot feel. Re-test at 8–12 weeks. If fasting glucose is climbing, that is your signal to cut the dose or come off — long before anything shows up symptomatically.
- Dose at night, on an empty stomach. GH release is pulsatile and largest during early sleep; food, and carbohydrate in particular, blunts the pulse through insulin. This is not a ritual — it is the same mechanism working with you rather than against you.
- Don't run a secretagogue through a high-carbohydrate surplus. The predicted problem is insulin resistance; adding a large carb load is pushing the same lever from the other end.
- Cycle rather than run continuously. Most of the predicted problems — fluid retention, carpal tunnel, glucose drift — are dose-and-duration dependent and reverse on cessation. Time off is the cheapest safety intervention available.
- If fluid retention is the issue, it usually resolves on a dose reduction long before it needs anything else. Reach for the dose before you reach for a diuretic.
What it does to your bloodwork
A fact about the assay, not a guess about the drug.
- IGF-1 drawn on-cycle is not your baseline — it is the drug working, and it will read high. If you want a real baseline, draw before starting or after a proper washout.
- Watch fasting glucose and HbA1c, because insulin resistance is the most likely thing to move and the one you will not feel.
- GHRP-6 and Hexarelin can raise prolactin and cortisol; if you are chasing an unexplained prolactin result, this is a candidate.
What it overlaps with
- Stacking two secretagogues that work by the same route is redundancy, not synergy. A GHRH analogue (CJC-1295, Sermorelin, Tesamorelin) plus a ghrelin mimetic (Ipamorelin, GHRP-2, GHRP-6) is the deliberate pairing — two different levers on the same axis. Two GHRH analogues together is paying twice for one lever.
Don't run this if
- Active or recent malignancy — the IGF-1 reasoning above.
- Diabetes or poor glycaemic control, unless you are monitoring fasting glucose and HbA1c and know what you are looking at.
- Untreated diabetic retinopathy.
The honest unknown
- Nobody has run long-term studies of intermittent secretagogue use in healthy adults. The specific unmeasured thing is what years of repeatedly pushing IGF-1 above your natural set point does — not whether a single cycle is tolerable, which it evidently is.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Fasted — and pre-bed is the best of the windows
Food is the problem here, and specifically carbohydrate and fat. Both trigger somatostatin release, and somatostatin is the brake on growth hormone — eating before the injection pharmacologically cancels it. Two clear hours either side.
Pre-bed is the strongest window because the largest natural GH pulse happens in the first hours of deep sleep, so you are stacking with it rather than asking the pituitary for something it is not primed for. Fasted pre-training is the second-best, for the same reason in a different rhythm.
Derived from half-life, route and mechanism — not from a dosing trial. Reasoned, and labelled as reasoned.
Tesamorelin reconstitution calculator
Research reconstitution calculator
Where to get Tesamorelin
Buy Tesamorelin at AminoWell USA →Tesamorelin — interference & stacking
Predicted from mechanism, not from an interaction study. There are no trials of these combinations — what follows is what the biology implies, so treat it as a reason to watch something, not as a finding.
What Tesamorelin moves on your bloodwork
These are the markers this compound is expected to move, and which direction. Knowing that in advance is mostly about NOT panicking: some of these moving is the compound working.
- IGF-1 (Insulin-like Growth Factor 1) — ↑ expected to rise
This is the point. IGF-1 rising is the compound doing its job — it is the stable downstream readout of a GH pulse.
What to do: Test it before you start and again at 6–8 weeks. It is the only number that tells you whether the product was real and the dose was enough. - Growth Hormone, Serum — ✕ unreliable here
A random GH level is close to meaningless here. GH is secreted in pulses during deep sleep and sits undetectable between them, so a daytime draw catches a trough almost every time — including when the compound is working perfectly.
What to do: Do not use GH to judge a secretagogue. Read IGF-1 instead. - Fasting Insulin — ↑ expected to rise
GH is a counter-regulatory hormone: it opposes insulin. Fasting insulin and glucose drifting up is the predicted trade-off, not a surprise.
What to do: Check fasting insulin and HbA1c at baseline and again at 8–12 weeks. This is the marker that decides whether you keep running it. - HbA1c (Hemoglobin A1c) — ↑ expected to rise
Same mechanism, longer window — a slow drift rather than a jump.
What to do: Pair it with fasting insulin; either alone can mislead. - Free T4 (Thyroxine) — ↓ expected to fall
GH accelerates the peripheral conversion of T4 to T3, so free T4 can fall while free T3 holds or rises. Read alone it looks like new hypothyroidism, and it usually isn't.
What to do: Run a full thyroid panel rather than TSH alone before concluding anything.
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Get the complete breakdown for Tesamorelin — inside the Academy alongside the full interactive Vault.
Unlock in the Academy — $10/mo →Everything above follows from one fact: these raise GH and therefore IGF-1. Nothing here needs a trial of the specific molecule.
Bloodwork to run alongside Tesamorelin
Run these before you start, and again after 8–12 weeks. A baseline you didn’t take is one you can never go back for.
| Marker | What it’s watching for |
|---|---|
| IGF-1 (Insulin-like Growth Factor 1) | The dosing target — this is the only GH peptide with real trial data |
| Fasting Insulin | Insulin sensitivity worsens across this whole class |
| HbA1c (Hemoglobin A1c) | Slower confirmation |
| Lipid Panel (Cholesterol, HDL, LDL, Triglycerides) | Visceral fat reduction should show here if it's working |
The Running GH Peptides or MK-677 panel covers these in one order — 9 markers, $132.30 with the discount applied.
Check results you already have → · All 102 markers A–Z
Tesamorelin — frequently asked questions
What is tesamorelin?
Tesamorelin is a stabilized GHRH (1-44) analog that stimulates your pituitary to release growth hormone. It's FDA-approved (Egrifta) to reduce visceral abdominal fat in adults with HIV and lipodystrophy — the only approved GHRH-analog drug.
How does tesamorelin burn belly fat?
It triggers a GH pulse, and visceral (deep abdominal) fat has more GH receptors and a higher lipolytic rate than subcutaneous fat — so the GH effect lands disproportionately on belly fat, largely sparing fat just under the skin.
How much visceral fat does tesamorelin reduce?
In pooled Phase III data (806 participants), tesamorelin reduced visceral adipose tissue by about 15.4% versus placebo at 26 weeks, while largely sparing subcutaneous fat. Individual results vary.
How is tesamorelin dosed?
Approved dosing has been daily subcutaneous (2 mg Egrifta; 1.4 mg Egrifta SV). A 2025 weekly-reconstitution formulation (Egrifta WR, 1.28 mg) improved convenience. Dosing must be prescriber-supervised; this is educational only.
Is tesamorelin FDA-approved?
Yes — as Egrifta / Egrifta SV / Egrifta WR, for excess abdominal fat in adults with HIV and lipodystrophy. It's the only FDA-approved GHRH-analog drug.
What are the side effects of tesamorelin?
Commonly injection-site reactions, joint pain and fluid retention. It raises IGF-1, so IGF-1 is monitored and it carries the class cancer caution; it's contraindicated in active malignancy.
References & further reading
- FDA approves F8 (Egrifta WR) tesamorelin for HIV lipodystrophy (2025)
- Tesamorelin research guide — mechanism, dosage, visceral fat
- Tesamorelin: complete guide to the FDA-approved GHRH analog
Want Coach Cam's exact Tesamorelin protocol?
Dosing schedules, stacking, cycle timing and my personal notes live inside the Academy — plus the full interactive Vault of 237 compounds & 350 supplements.
Join the Academy — $10/mo →What Tesamorelin is used for
Tesamorelin appears under 2 goals in the Vault’s goal router, grouped by the mechanism it works through rather than by how much trial evidence exists. Each link opens that pathway in full, with the alternatives beside it and the bloodwork that tests it.